Fibroblast Growth Factor Receptor 2 (FGFR2) (N-Term) antibody

Antigen: Fibroblast Growth Factor Receptor 2 (FGFR2)

Synonyms: Fgfr2, BEK, JWS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, CD332, K-SAM, FLJ98662, Bek, svs, Fgfr7, Fgfr-2, Fgfr-7, KGFRTr, AU043015, AW556123, MGC102519, wu:fc56c05, FGFR2, cek3, FGF-R, FGFR2IIIb, fgfr72IIIb, FGFR, bek, jws, cfd1, ect1, kgfr, tk14, tk25, bfr-1, cd332, k-sam, xfgfr2, DKFZp469H1521

Binding Site: N-Term

Clonality: Polyclonal

Host: Rabbit

Reactivity: Human, Rat (Rattus), Primate

Conjugate: Un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (IHC), ELISA

Certificates: ISO 9001:2008

Catalog no.: ABIN391965

Additional Information

Alternative name: FGFR2

Gene ID: 2263

UniProt: P21802

Immunogen: This FGFR2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 15~44 amino acids from the N-terminal region of human FGFR2.

Isotype: Ig

Description: Other names: fibroblast growth factor receptor 2

Characteristics: Purified Rabbit Polyclonal Antibody (Pab)

Specificity: This FGFR2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 15~44 amino acids from the N-terminal region of human FGFR2.

Molecular Weight: 92025 DA

Comments:

Background: FGFR2 is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in the gene are associated with many craniosynostotic syndromes and bone malformations. The genomic organization of the gene encompasses 20 exons. Alternative splicing in multiple exons, including those encoding the Ig-like domains, the transmembrane region and the carboxyl terminus, results in varied isoforms which differ in structure and specificity. Isoform 1 has equal affinity for aFGF and bFGF but does not bind KGF.

Synonyms: Fgfr2, BEK, JWS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, CD332, K-SAM, FLJ98662, Bek, svs, Fgfr7, Fgfr-2, Fgfr-7, KGFRTr, AU043015, AW556123, MGC102519, wu:fc56c05, FGFR2, cek3, FGF-R, FGFR2IIIb, fgfr72IIIb, FGFR, bek, jws, cfd1, ect1, kgfr, tk14, tk25, bfr-1, cd332, k-sam, xfgfr2, DKFZp469H1521

Application Details

Application Notes: The suggested dilution is: ELISA~~1:1,000 Western blotting~~1:100~500 Immunohistochemistry~~1:50~100 Immunofluorescence

Concentration: 0.25 mg/ml

Purification: Purified

Buffer: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.

Storage: Maintain refrigerated at 2-8 deg C for up to 6 months. For long term storage store at -20 deg C in small aliquots to prevent freeze-thaw cycles

Research Area: Phospho-specific antibodies, Cell Signaling, Protein Modifications, Cell Structure, Cell Cycle

Restrictions: For Research Use only

Images

Western blot analysis of anti-hFGFR2-R22 Pab (ABIN391965) in 293 cell line lysates transiently transfected with the FGFR2 gene (2ug/lane). hFGFR2-R22(arrow) was detected using the purified Pab (1:30 dilution).

Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry. clinical relevance has not been evaluated. BC = breast carcinoma. HC = hepatocarcinoma.

C:FGFR2/isolectinB4 (C) and FGFR1/isolectinB4 (D) staining of apparent mesenchymal cells and the subpopulation of endothelial cells. Virtually all other dispersed apparent mesenchymal cells express FGFR1 and FGFR2 (merged image in E). F: FGFR2 (F) and FGFR1 (G) staining in clustered cells of epithelial origin (inferred by morphology here) demonstrating that epithelial cells express both FGFR1 and FGFR2 (merged image with DAPI staining in H).

Publications

Product: Katoh, Katoh: "FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26." in: International journal of oncology, Vol. 22, Issue 5, pp. 1155-9, 2003 (PubMed).

Katoh, Katoh: "Recombination cluster around FGFR2-WDR11-HTPAPL locus on human chromosome 10q26." in: International journal of molecular medicine, Vol. 11, Issue 5, pp. 579-83, 2003 (PubMed).

Fomenkov, Huang, Topaloglu et al.: "P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome." in: The Journal of biological chemistry, Vol. 278, Issue 26, pp. 23906-14, 2003 (PubMed).

Goriely, McVean, Röjmyr et al.: "Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line." in: Science (New York, N.Y.), Vol. 301, Issue 5633, pp. 643-6, 2003 (PubMed).

Freeman, Gangula, Welm et al.: "Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation." in: Cancer research, Vol. 63, Issue 19, pp. 6237-43, 2003 (PubMed).